Payload Information
General Information of This Payload
| Payload ID | PAY0UAKUK |
|||||
|---|---|---|---|---|---|---|
| Name | P3 payload |
|||||
| Synonyms |
P3 payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C51H53F2N7O6 |
|||||
| Isosmiles | CN1C(C2=CC3=C(C=C2C(N([C@@H](C4)C)CC5=C4C=CC=C5)=O)CN(C(CC6=CC=C(OCCN7CCOCC7)C=C6)=O)CC3)=CC(C(N(C(C=N8)=CN8C(F)F)C9=CC=C(O)C=C9)=O)=C1C |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C51H53F2N7O6/c1-33-24-36-6-4-5-7-38(36)31-58(33)49(63)46-27-39-30-57(48(62)25-35-8-14-43(15-9-35)66-23-20-56-18-21-65-22-19-56)17-16-37(39)26-45(46)47-28-44(34(2)55(47)3)50(64)60(40-10-12-42(61)13-11-40)41-29-54-59(32-41)51(52)53/h4-15,26-29,32-33,51,61H,16-25,30-31H2,1-3H3/t33-/m1/s1
|
|||||
| InChIKey |
WOSWSRHAMIFNQP-MGBGTMOVSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
898.024 |
Polar area |
125.61 |
||
Complexity |
2672.99807 |
xlogp Value |
7.70162 |
|||
Heavy Count |
66 |
Rot Bonds |
12 |
|||
Hbond acc |
10 |
Hbond Donor |
1 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
NY920-P1-L12-P3 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.033 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P3 was tested in KHM-1B
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KHM-1B cells | CVCL_2972 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.174 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P3 was tested in KMS-21-BM
|
||||
| In Vitro Model | Multiple myeloma | KMS-21-BM cells | CVCL_2991 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.185 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P3 was tested in NCI-H929
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 1 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P3 was tested in KMS-27
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KMS-27 cells | CVCL_2993 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.07 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P3 was tested in AMO-1
|
||||
| In Vitro Model | Multiple myeloma, Plasma cell myeloma | AMO-1 cells | CVCL_1806 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 10 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P3 was tested in MOLP-8
|
||||
| In Vitro Model | Plasma cell myeloma | MOLP-8 cells | CVCL_2124 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 50 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P3 was tested in WSU-DLCL2
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
221.8 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P3 was tested in RL
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | RL cells | CVCL_1660 | ||
NY920-P1-L17-P3 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.046 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P3 was tested in KHM-1B
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KHM-1B cells | CVCL_2972 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.121 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P3 was tested in NCI-H929
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.257 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P3 was tested in KMS-27
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KMS-27 cells | CVCL_2993 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.287 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P3 was tested in Ke97
|
||||
| In Vitro Model | Bladder carcinoma | Ke97 cells | CVCL_3386 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.32 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P3 was tested in KMS-21-BM
|
||||
| In Vitro Model | Multiple myeloma | KMS-21-BM cells | CVCL_2991 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.832 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P3 was tested in AMO-1
|
||||
| In Vitro Model | Multiple myeloma, Plasma cell myeloma | AMO-1 cells | CVCL_1806 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 5 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P3 was tested in MOLP-8
|
||||
| In Vitro Model | Plasma cell myeloma | MOLP-8 cells | CVCL_2124 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 50 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P3 was tested in WSU-DLCL2
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 250 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P3 was tested in RL
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | RL cells | CVCL_1660 | ||
CD74 Milatuzumab DANAPAE152C S375C-P1-L12-P3 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.292 nM
|
High CD74 expression (CD74 +++) | ||
| Method Description |
CD74 Milatuzumab DANAPAE152C S375C-P1-L12-P3 was tested in EOL-1
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||